Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

CAR T-cell therapy

This page shows the latest CAR T-cell therapy news and features for those working in and with pharma, biotech and healthcare.

Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer

Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer

Kite, a Gilead company, has reported positive three-year follow-up results from an ongoing study of its CAR T-cell therapy Tecartus (brexucabtagene autoleucel) in relapsed/refractory B-cell acute ... The positive results come just days after the company

Latest news

More from news
Approximately 7 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • CAR-T cell therapy in oncology CAR-T cell therapy in oncology

    Next generation CAR-T cell therapy. First generation, autologous CAR-T cell immunotherapies have demonstrated significant clinical promise. ... However, it is well recognised that the full potential of CAR-T cell therapy has yet to be fully exploited.

  • Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world

    EBCs also demonstrate positive data and are bringing novel therapies to market in complex areas of medicine, including gene therapy, CAR T-cell therapy and rare diseases. ... These visuals got the message across in an engaging, novel and efficient manner

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    Chimeric antigen receptor T-cell therapy. Chimeric antigen receptor (CAR) T-cell therapy consists of engineering receptors in the body that selectively interact with cancer cells, inducing cell death without affecting ... CAR-T therapy has potential

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... We estimate the cost [of making a CAR-T cell therapy for a single

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The analysts predict the drug will be priced at around $550,

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Precision versus personalised medicine Precision versus personalised medicine

    Targeted therapy’ is a broad term that often refers to the use of drugs that target specific proteins, cell surface molecules, or genes. ... ESMO Daily Reporter. CAR-T-cell therapy. Available at: . Accessed November 2022. Qin VM, et al. Cancers

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • Precision paediatrics: Treating patients with CAR-T

    He is part of a team using a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy, which is transforming outcomes for children who would otherwise have no treatment options left. ... SA: CAR-T cell therapy is an innovative immunotherapy that

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

  • Innovation in pharma: the highs and lows of the current healthcare economy

    Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US. ... The approach is to deliver treatments which restore or establish normal cell

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...

Quick links